EU Chemicals Agency Backs CBD Reproductive Toxicant Classification

Europe’s CBD industry is confronting the most direct regulatory threat it has faced in years: the European Chemicals Agency‘s Risk Assessment Committee adopted an opinion in March 2026 recommending that cannabidiol be classified as a presumed human reproductive toxicant. If the European Commission confirms that recommendation, CBD would be automatically prohibited in cosmetic products across all 27 member states — a market worth more than $750 million annually in Europe.

The scale of the exposure is considerable. European CBD revenues total approximately $2.5 billion annually. An automatic prohibition under EU cosmetics rules would affect every topical balm, moisturizer, and serum containing the compound currently sold anywhere in the bloc.

What the ECHA process found

The classification process traces back to April 2023, when France first filed its intention to submit a formal classification and labelling dossier for CBD through ECHA’s harmonised classification system. France’s Agency for Food, Environmental and Occupational Health & Safety — known by its French acronym ANSES — completed the formal submission in February 2025, and ECHA opened a public consultation on the proposal from March 17, 2025 to May 16, 2025.

After reviewing the submission and the comments received, ECHA’s Risk Assessment Committee formally adopted its opinion on March 6, 2026. The committee endorsed the classification proposed by ANSES: that CBD be designated a Category 1B reproductive toxicant — meaning it is presumed to pose reproductive toxicity to humans — and that it also carry a hazard designation indicating risk to breastfed children. The ECHA classification registry lists the opinion as adopted, with the legal deadline for European Commission action set for August 2026.

The scientific basis underpinning that conclusion is disputed by industry. The ANSES dossier drew heavily on animal studies from trials of the CBD-based pharmaceutical Epidiolex, in which rats were subjected to doses of 300 milligrams per kilogram of body weight. Critics have argued those exposure levels bear no meaningful relationship to the amounts consumers encounter through cosmetics or dietary supplements.

A second EU opinion — and a different answer

The same month the Risk Assessment Committee adopted its opinion, the European Commission’s Scientific Committee on Consumer Safety reached a very different conclusion through a parallel process. The committee published its final advice on April 24, 2026, finding that CBD is safe for use in dermal and oral cosmetic products at concentrations up to 0.19%. THC impurities were found acceptable at trace concentrations.

The contrast matters. The ECHA process applies a hazard-based framework — assessing CBD’s intrinsic toxicological properties regardless of typical consumer exposure — while the consumer safety committee takes a risk-based approach, evaluating whether CBD poses a real danger at concentrations that actually appear in commercial products. Both are legitimate scientific frameworks under EU law, but they can produce divergent outcomes for the same substance.

That divergence shapes the path forward for the cosmetics sector. Under EU rules governing cosmetic products, any substance designated as a carcinogenic, mutagenic or reprotoxic — CMR — Category 1A or 1B substance is automatically prohibited from use in cosmetics across the single market. A specific scientific exemption can, however, be sought. The consumer safety committee’s finding that CBD is safe in cosmetics at a defined concentration level is precisely the kind of evidence that would support an exemption application.

The RAC opinion is not a final regulatory determination. It is a scientific hazard assessment that ECHA will forward to the European Commission, which will then decide how to proceed. Under standard procedure, the Commission takes between three and nine months before publishing a draft decision. That draft is then subject to member state consultation before it becomes binding EU regulation — a timeline that gives industry multiple opportunities to submit data and push for a different outcome.

Industry challenge and France’s early enforcement

Earlier legal battles over CBD’s status in Europe do not resolve this particular regulatory question. France’s attempt to ban CBD flowers in 2022 was blocked as inconsistent with free-movement principles. The Court of Justice of the EU’s 2020 ruling in the Kanavape case established that hemp-derived CBD is not a narcotic drug. Neither outcome addresses a CMR classification, which operates through an entirely separate legal mechanism.

The European Industrial Hemp Association, which represents producers, manufacturers, and CBD retailers across the continent, has announced it will challenge the Category 1B designation and push for reclassification to Category 2 — a lower-tier “suspected” toxicant designation the group says would better reflect the available evidence and the uncertainties in the underlying data. The association also plans to pursue a formal cosmetics exemption through the derogation mechanism built into EU cosmetics rules, and is in active discussions with the European Commission on that front. Italian CBD company Enecta and representatives from European agricultural cooperative networks have separately flagged concerns about the implications for legal certainty and investment across the supply chain.

France is already moving ahead of any Commission determination. The country’s food regulation enforcement body announced in April 2026 that it is preparing a national control plan targeting all food products and supplements containing CBD, THC, or any other cannabinoid. French industry groups have described the move as an overreach that goes beyond the actual public health findings from French health authorities, warning it would severely impact a sector that directly employs some 15,000 people and distributes through roughly 2,500 specialized retailers and an estimated 20,000 pharmacies.

As Greece recently demonstrated by moving toward a hemp flower ban despite warnings of conflict with EU law, member states across Europe are not waiting for Commission direction before tightening their approaches to cannabinoid products. For the CBD sector, the regulatory question now rests with the Commission: whether to endorse the RAC’s classification, and how to weigh the consumer safety committee’s finding that CBD is safe at concentrations well within the range of typical commercial use.